Retatrutide

Retatrutide research material, available in 10 mg, 20 mg, 40 mg vials. For in-vitro research only.

• In vitro the peptide showed balanced activity at the glucagon and GLP-1 receptors but more activity at the GIP receptor, which the authors describe as a triple agonist profile rather than an equipotent one. [1]
• In obese mice the authors attributed the body weight change to two separable contributions: an increase in energy expenditure mediated by the glucagon receptor added to a reduction in calorie intake driven by the GIP and GLP-1 receptors. [1]
• In db/db mice the peptide lowered expression of pro-inflammatory and pro-fibrotic markers in the kidney more than a GLP-1 receptor agonist or a dual agonist comparator, while it did not lower blood glucose more than those comparators. [2]
• In rodent tumor models the peptide delayed tumor onset and reduced tumor volume relative to controls, with immune changes that included raised circulating IL-6 and more antigen presenting cells. [3]

Compound

Retatrutide

Purity

99.10% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg · 20 mg · 40 mg

Catalog / lot

RV-0006 / RV-24-0006-3

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.